Details of the Drug

General Information of Drug (ID: DMZ36RN)

Drug Name

Mazindol

Synonyms

mazindol; Mazanor; Sanorex; Teronac; Mazildene; 22232-71-9; Magrilon; Dimagrir; Mazindolum; Mazindole; Mazindolum [INN-Latin]; Terenac; AN 448; Mazindol [USAN:BAN:INN]; SAH 42548; CCRIS 3152; DEA No 1605; 5-(4-Chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol; 5-(4-Chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol; HSDB 3112; SA 42-548; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo[2,1-a]isoindole; EINECS 244-857-0; S 42548; CHEMBL781; 5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol; BRN 0546547; Diestet; Sanjorex; Solucaps; Teronak; Mazindol Medix Brand; Mazindol Novartis Brand; Mazindol Searle Brand; Mazindol Wyeth Brand; Medix Brand of Mazindol; Novartis Brand of Mazindol; Searle Brand of Mazindol; Wyeth Brand of Mazindol; AN 448;AN448; AN-448; Mazanor (TN); SANOREX (TN); Sanorex (TN); Mazindol (JAN/USP/INN); (+-)-5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole; 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol; 5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; 5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro; [3H]mazindol

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Approved	[1], [2]

Therapeutic Class

Central Nervous System Stimulants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

284.74

Topological Polar Surface Area (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Bioavailability: 93% of drug becomes completely available to its intended biological destination(s) [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 10 - 13 hours [4]
Metabolism: The drug is metabolized via the hepatic [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.11695 micromolar/kg/day [6]

Chemical Identifiers

Formula: C16H13ClN2O
IUPAC Name: 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol
Canonical SMILES: C1CN2C(=N1)C3=CC=CC=C3C2(C4=CC=C(C=C4)Cl)O
InChI: InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
InChIKey: ZPXSCAKFGYXMGA-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4020
ChEBI ID: CHEBI:6702
CAS Number: 22232-71-9
DrugBank ID: DB00579
TTD ID: D0H8QL
VARIDT ID: DR00850

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Modulator	[7], [8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Obesity

ICD Disease Classification

5B81

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Norepinephrine transporter (NET)	DTT	SLC6A2	7.05E-01	7.02E-03	0.07

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mazindol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Increased risk of hyperpyrexia by the combination of Mazindol and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[17]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Mazindol and Droxidopa.	Autonomic nervous system disorder [8D87]	[18]
Linezolid	DMGFPU2	Major	Additive hypertensive effects by the combination of Mazindol and Linezolid.	Bacterial infection [1A00-1C4Z]	[17]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Mazindol and Ethanol.	Cystitis [GC00]	[19]
Selegiline	DM6034S	Major	Increased risk of hyperpyrexia by the combination of Mazindol and Selegiline.	Depression [6A70-6A7Z]	[17]
Isocarboxazid	DMAF1NB	Major	Additive hypertensive effects by the combination of Mazindol and Isocarboxazid.	Depression [6A70-6A7Z]	[17]
Tranylcypromine	DMGB5RE	Major	Additive hypertensive effects by the combination of Mazindol and Tranylcypromine.	Depression [6A70-6A7Z]	[20]
Phenelzine	DMHIDUE	Major	Increased risk of hyperpyrexia by the combination of Mazindol and Phenelzine.	Depression [6A70-6A7Z]	[17]
Esketamine	DMVU687	Major	Additive hypertensive effects by the combination of Mazindol and Esketamine.	Depression [6A70-6A7Z]	[21]
Procarbazine	DMIK367	Major	Additive hypertensive effects by the combination of Mazindol and Procarbazine.	Hodgkin lymphoma [2B30]	[17]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Mazindol and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[22]
Promethazine	DM6I5GR	Moderate	Antagonize the effect of Mazindol when combined with Promethazine.	Nausea/vomiting [MD90]	[23]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Mazindol and Bupropion.	Nicotine use disorder [6C4A]	[24]
Safinamide	DM0YWJC	Moderate	Decreased metabolism of Mazindol caused by Safinamide mediated inhibition of non-CYP450 enzyme.	Parkinsonism [8A00]	[25]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Mazindol and Rasagiline.	Parkinsonism [8A00]	[17]
Mesoridazine	DM2ZGAN	Moderate	Antagonize the effect of Mazindol when combined with Mesoridazine.	Schizophrenia [6A20]	[26]
Thioridazine	DM35M8J	Moderate	Antagonize the effect of Mazindol when combined with Thioridazine.	Schizophrenia [6A20]	[26]
Perphenazine	DMA4MRX	Moderate	Antagonize the effect of Mazindol when combined with Perphenazine.	Schizophrenia [6A20]	[23]
Trifluoperazine	DMKBYWI	Moderate	Antagonize the effect of Mazindol when combined with Trifluoperazine.	Schizophrenia [6A20]	[23]
-----------


⏷ Show the Full List of 19 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4797).
2	Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine. 2000 Oct;13(2):193-9.
3	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
10	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
11	Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
12	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
13	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
14	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
15	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
16	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
17	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
18	Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
19	Product Information. Suprenza (phentermine). Akrimax Pharmaceuticals, Cranford, NJ.
20	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
21	Cerner Multum, Inc. "Australian Product Information.".
22	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
23	Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
24	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
25	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
26	Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]